ovarian cancer	is a	malignant tumor of the ovary
ovarian cancer	has histology	high-grade serous carcinoma
ovarian cancer	has histology	endometrioid carcinoma
ovarian cancer	has histology	clear cell carcinoma
ovarian cancer	has histology	mucinous carcinoma
ovarian cancer	has histology	low-grade serous carcinoma
ovarian cancer	associated with	BRCA1 mutation
ovarian cancer	associated with	BRCA2 mutation
ovarian cancer	associated with	HRD
ovarian cancer	associated with	Lynch syndrome
BRCA1 mutation	increases risk for	ovarian cancer
BRCA2 mutation	increases risk for	ovarian cancer
age	is risk factor for	ovarian cancer
nulliparity	is risk factor for	ovarian cancer
early menarche	is risk factor for	ovarian cancer
late menopause	is risk factor for	ovarian cancer
obesity	is risk factor for	ovarian cancer
endometriosis	is risk factor for	ovarian cancer
family history	is risk factor for	ovarian cancer
CA-125	is tumor marker for	ovarian cancer
HE4	is tumor marker for	ovarian cancer
CA-125	elevation correlates with	disease burden
transvaginal ultrasound	is used for	evaluation of adnexal mass
CT scan	is used for	staging of ovarian cancer
MRI	is used for	staging of ovarian cancer
laparoscopy	is used for	tumor assessment
biopsy	is used for	diagnosis of ovarian cancer
cytology	is used for	detection of malignant cells in ascites
CA-125	used for	monitoring therapy response
FIGO stage	determines	prognosis
tumor grade	predicts	prognosis
residual disease	predicts	recurrence
BRCA1 mutation	predicts	PARP inhibitor sensitivity
BRCA2 mutation	predicts	PARP inhibitor sensitivity
HRD	predicts	platinum sensitivity
histology	predicts	recurrence pattern
cytoreductive surgery	is standard treatment for	ovarian cancer
cytoreductive surgery	aims for	optimal debulking
optimal debulking	improves	survival
carboplatin	is used for	first-line chemotherapy
paclitaxel	is used for	first-line chemotherapy
carboplatin	is combined with	paclitaxel
intraperitoneal chemotherapy	used for	ovarian cancer with residual disease
bevaczizumab	added to	chemotherapy
bevacizumab	added to	chemotherapy
PARP inhibitors	used for	maintenance therapy
olaparib	is a	PARP inhibitor
niraparib	is a	PARP inhibitor
rucaparib	is a	PARP inhibitor
PARP inhibitors	improve	progression-free survival
bevacizumab	improves	progression-free survival
neoadjuvant chemotherapy	used in	bulky disease
adjuvant chemotherapy	used in	early-stage ovarian cancer
surgical staging	performed for	ovarian cancer
lymphadenectomy	performed for	ovarian cancer staging
omentectomy	performed for	debulking of ovarian cancer
surgery	followed by	chemotherapy
intraperitoneal chemotherapy	leads to	toxicity
chemotherapy	causes	myelosuppression
chemotherapy	causes	neuropathy
surgery	associated with	perioperative morbidity
ascites	indicates	peritoneal spread
peritoneal carcinomatosis	indicates	advanced stage
pleural effusion	indicates	metastasis
stage IV ovarian cancer	has poor prognosis	compared to early-stage
advanced-stage ovarian cancer	has poor prognosis	compared to early-stage
CA-125 normalization	indicates	response to therapy
HE4 normalization	indicates	response to therapy
ovarian cancer recurrence	occurs in	peritoneum
platinum sensitivity	predicts	chemotherapy response
platinum resistance	defines	relapse risk
maintenance therapy	provides	disease control
clinical trial	offers	novel therapies
targeted therapy	indicated for	BRCA-mutant ovarian cancer
tissue biopsy	guides	treatment selection
genetic testing	informs	risk management
risk-reducing salpingo-oophorectomy	reduces	risk for ovarian cancer
chemotherapy toxicity	limits	treatment duration
debulking	reduces	tumor burden
tumor burden	informs	prognosis
liver metastasis	indicates	stage IV disease
ovarian cancer	treated with	platinum-based chemotherapy
bevacizumab	indicated for	platinum-resistant ovarian cancer
niraparib	indicated for	maintenance therapy in ovarian cancer
second-line chemotherapy	includes	carboplatin-based regimens
interval debulking surgery	performed after	neoadjuvant chemotherapy
interval debulking surgery	reduces	residual disease
intraperitoneal chemotherapy	associated with	catheter-related complications
catheter-related infection	occurs with	intraperitoneal chemotherapy
ascites	causes	abdominal distension
peritoneal metastasis	leads to	ascites
debulking surgery	reduces	tumor burden
complete debulking	defines	favorable prognosis
complete debulking	reduces	recurrence risk
progression-free survival	is endpoint of	ovarian cancer trials
overall survival	is endpoint of	ovarian cancer trials
imaging	identifies	peritoneal metastasis
surgical staging	provides	prognostic information
BRCA testing	informs	PARP inhibitor eligibility
prognosis	improves	with complete cytoreduction
no residual disease	defines	favorable prognosis
